Preliminary results from the trial of a malaria vaccine show that it protected nearly half of the children who received it from bouts of serious malaria, scientists said Tuesday. The vaccine, known as RTS,S and made by GlaxoSmithKline, has been in development for more than 25 years, initially for the American military and now with most of its support from the Bill and Melinda Gates Foundation. … [Read more...]
Study Finds Malaria Vaccine Candidate, RTS,S Significantly Reduces Malaria Risk in African Infants
First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & … [Read more...]
RTS,S Malaria Vaccine
QUESTION: What information can you provide on this vaccine candidate? ANSWER: RTS,S is a vaccine candidate against Plasmodium falciparum malaria which works by encouraging the host's body to produce antibodies and T cells which diminish the malaria parasite's ability to survive and reproduce in the liver. Produced by GlaxoSmithKline, RTS,S is the first vaccine candidate against … [Read more...]
GSK and Johnson & Johnson Announce Malaria Vaccine Collaboration
GlaxoSmithKline Biologicals (GSK Bio) and Crucell NV (Johnson & Johnson) have announced a collaboration to develop a vaccine approach aimed at boosting the efficacy of the world’s most clinically advanced malaria vaccine candidate, RTS,S. The PATH Malaria Vaccine Initiative (MVI) today congratulated the companies on the partnership. "We are excited by the potential of this new endeavor for … [Read more...]